Mr. Carroll secured important wins for the pharmaceutical industry in the U.S. Court of Appeals for the First Circuit. In May 2016, the First Circuit affirmed the dismissal with prejudice of purported securities fraud class action cases against a major Boston pharmaceutical company. In doing so, the court emphasized that the plaintiff’s use of so-called “confidential witnesses” — even when there are many of them — is no substitute for specific factual allegations of fraud. In another frequently cited First Circuit win for a pharmaceutical company, the court emphasized that drug companies have no obligation to immediately publicly disclose even very negative adverse events of a drug and that securities laws permit — indeed, require — that issuers reasonably investigate important developments prior to public disclosure. Mr. Carroll, on behalf of a German-based global pharmaceutical and chemical company, also won denial of a preliminary injunction motion seeking to enjoin a shareholder vote on whether to approve the company’s proposed $7 billion acquisition of a Massachusetts-based life science company.
Mr. Carroll also has handled significant antitrust matters in the financial services and pharmaceutical industries. His recent engagements include the defense of a branded pharmaceutical company in a so-called “pay for delay” case and a case alleging collusion among private equity firms.
Mr. Carroll is handling a number of purported class actions for major national life insurers and is defending a variety of purported class and individual actions in the life, disability and casualty insurance contexts. He won an appeal for one of the nation’s largest mutual fund complexes that reversed a lower court’s refusal to dismiss three putative class actions involving allegations of improper mutual fund "market timing" activities. Mr. Carroll also represented investment advisers in regulatory inquiries and civil litigations in connection with the Bernard Madoff scandal. He also is defending one of the nation’s leading providers of variable annuities in class actions filed in multiple jurisdictions. Mr. Carroll regularly represents special committees and corporations in connection with derivative actions, and has conducted investigations of alleged misconduct levied by whistleblowers.
Mr. Carroll also is defending multiple ERISA class action cases, particularly in the financial services industry. In this regard he obtained a rare voluntary dismissal of a class action, pending in the Southern District of New York, against ERISA fiduciaries alleged to have ignored prudent risk concentration/diversification guidelines. He is currently defending several ERISA class actions alleging that plan participants paid excessive fees on a variety of investment options, including proprietary funds. In 2017, he successfully tried an ERISA class action to conclusion in the District of Massachusetts.
Mr. Carroll’s practice also includes representing corporations and individuals in matters before the SEC, the Massachusetts Attorney General’s Office and the Massachusetts Securities Division. His current engagements include matters before each of those regulators. He has defended a variety of civil enforcement actions and regulatory inquiries relating to allegations of misleading disclosure and claims that for-profit educational institutions and subprime lenders violated state consumer protection laws.
Mr. Carroll has utilized the Private Securities Litigation Reform Act to obtain a rare denial of a class certification motion in a purported 10b-5 securities fraud class action. He also argued the first Rule 23 (f) class certification appeal accepted by the First Circuit.
Mr. Carroll often litigates a variety of covenant-not-to-compete and "employee raiding" cases on behalf of several Massachusetts high-technology firms. He also has experience trying cases before arbitration panels of FINRA, AAA and ARIAS. In addition, he has tried a whistleblower case to conclusion before a Department of Labor administrative law judge.
Mr. Carroll has been a guest lecturer at the MIT Sloan School of Management on matters relating to insider trading and the federal securities laws. He is a former member of Skadden’s Policy Committee, the firm’s governing body. Mr. Carroll repeatedly has been selected for inclusion in Chambers USA: America’s Leading Lawyers for Business and The Best Lawyers in America. He also was named as one of the 500 Leading Lawyers in America by Lawdragon and has been named in The Legal 500 U.S. Mr. Carroll was named Best Lawyers’ 2021 Boston Bet-the-Company Litigation Lawyer of the Year and a 2019 Trials MVP by Law360, as well as a 2018 Client Choice Award winner as an attorney who “stands apart for excellent client care.” He has repeatedly been named a BTI Client Service All-Star by The BTI Consulting Group for providing outstanding client service. “All-Stars” are nominated unprompted in interviews with corporate counsel at Fortune 1000 and other large organizations.
In addition to courts in Massachusetts, he is admitted to practice in the U.S. Supreme Court, the U.S. Court of Appeals including the Federal, First, Second, Third, Fifth, Seventh and Ninth Circuits and numerous federal district courts across the country. Mr. Carroll’s practice is not limited to New England; he regularly litigates in courts throughout the United States.